M F Scanlon
Dados Biográficos
| ID | 4352874 |
|---|---|
| NOME | M F Scanlon |
| PRENOMES | M F |
| SOBRENOME | Scanlon |
| ASSINATURA | SCANLON M F |
| AFILIAÇÕES | University of Wales |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 2 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 2 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 1999 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2004 |
| ÍNDICE H | 0 |
Somatic characteristics and cardiovascular risk factors in growth hormone deficiency
The purpose of the present study was to identify the effect of treatment with recombinant human growth hormone (rhGH) on seven somatic characteristics and eight clinical cardiovascular risk factors. Twenty‐seven male and 24 female patients between the ages of 21 and 60 years were examined. The investigation was a double‐blind, placebo‐controlled study of 12 months duration. Patients were assigned randomly to treatment (T) and placebo (P) groups. …
Strength and its relationship to changes in fat-free mass, total body potassium, total body water and IGF-1 in adults with growth hormone deficiency
The present investigation examined changes in strength in growth hormone deficient (GHD) adults following treatment with recombinant human growth hormone (rhGH), and assessed their relationship to changes in fat-free mass (FFM), total body potassium (TBK), total body water (TBW), the concentration of TBK and TBW per kg FFM, and insulin like growth factor-1 (IGF-1). The investigation was double-blind and placebo-controlled for a period of 6 months…
Sem obras proeminentes nesta página.
Strength and its relationship to changes in fat-free mass, total body potassium, total body water and IGF-1 in adults with growth hormone deficiency
The present investigation examined changes in strength in growth hormone deficient (GHD) adults following treatment with recombinant human growth hormone (rhGH), and assessed their relationship to changes in fat-free mass (FFM), total body potassium (TBK), total body water (TBW), the concentration of TBK and TBW per kg FFM, and insulin like growth factor-1 (IGF-1). The investigation was double-blind and placebo-controlled for a period of 6 months…
Somatic characteristics and cardiovascular risk factors in growth hormone deficiency
The purpose of the present study was to identify the effect of treatment with recombinant human growth hormone (rhGH) on seven somatic characteristics and eight clinical cardiovascular risk factors. Twenty‐seven male and 24 female patients between the ages of 21 and 60 years were examined. The investigation was a double‐blind, placebo‐controlled study of 12 months duration. Patients were assigned randomly to treatment (T) and placebo (P) groups. …
Biology (2 obras) · Endocrinology (2 obras) · Growth hormone (2 obras) · Growth Hormone and Insulin-like Growth Factors (2 obras) · Hormone (2 obras) · Internal Medicine (2 obras) · Medicine (2 obras) · Placebo (2 obras) · Alternative medicine (1 obras) · Animal science (1 obras)